Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$0.67
+13.9%
$0.45
$0.22
$1.29
$36.32M0.8819.44 million shs4.06 million shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$7.50
+10.8%
$5.17
$2.92
$11.20
$43.68M-1.81216,393 shs138,258 shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$2.33
-2.1%
$2.36
$0.97
$9.79
$11.42M0.862.66 million shs218,759 shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$0.83
+6.2%
$0.88
$0.61
$6.80
$44.03M1.22123,091 shs74,562 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
+13.93%-20.55%+99.11%+49.71%-33.26%
KALA BIO, Inc. stock logo
KALA
KALA BIO
+10.78%-7.29%+48.51%+100.00%+13.98%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-2.10%-14.96%-6.05%+18.88%-27.19%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
+6.21%-10.94%+3.54%-6.66%-87.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2.4049 of 5 stars
3.62.00.00.02.01.70.6
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.5078 of 5 stars
3.52.00.04.40.60.80.6
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
2.5564 of 5 stars
3.53.00.00.01.12.50.6
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
3.2726 of 5 stars
3.54.00.00.02.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
3.25
Buy$2.83324.53% Upside
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.00
Buy$13.0073.33% Upside
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
3.00
Buy$14.00500.86% Upside
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
3.00
Buy$4.50443.28% Upside

Current Analyst Ratings Breakdown

Latest PHIO, PRLD, KALA, and CGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
6/26/2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
6/25/2025
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
6/5/2025
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/2/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$15.00
5/27/2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $3.00
5/23/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
5/8/2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $4.00
5/5/2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/A$0.31 per shareN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
$3.89M12.44N/AN/A$2.02 per share3.71
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/A$0.69 per shareN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$7M6.68N/AN/A$2.39 per share0.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$33.97M-$0.74N/AN/AN/AN/A-194.42%-115.14%8/6/2025 (Estimated)
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$38.51M-$8.24N/AN/AN/AN/A-369.29%-64.99%8/5/2025 (Estimated)
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$7.15M-$6.42N/A0.62N/AN/A-105.65%-89.19%8/13/2025 (Estimated)
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$127.17M-$1.69N/AN/AN/AN/A-89.18%-69.26%8/11/2025 (Estimated)

Latest PHIO, PRLD, KALA, and CGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.11N/AN/AN/AN/AN/A
8/13/2025N/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$0.36N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.45N/AN/AN/AN/AN/A
8/5/2025Q2 2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$1.82N/AN/AN/AN/AN/A
5/6/2025Q1 2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.12-$0.14-$0.02-$0.14N/AN/A
5/6/2025Q1 2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.47-$0.42+$0.05-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/A
2.09
2.09
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.19
1.99
1.99
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/A
10.58
10.58
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/A
5.18
5.18

Institutional Ownership

CompanyInstitutional Ownership
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
43.35%
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
57.31%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
79.72%

Insider Ownership

CompanyInsider Ownership
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
14.40%
KALA BIO, Inc. stock logo
KALA
KALA BIO
8.32%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.59%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
63.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2061.99 million53.07 millionNot Optionable
KALA BIO, Inc. stock logo
KALA
KALA BIO
306.45 million5.92 millionNot Optionable
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
104.80 million4.77 millionNot Optionable
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
12056.46 million20.38 millionOptionable

Recent News About These Companies

Prelude Therapeutics Founder Acquires 28% More Stock
Prelude Therapeutics CEO buys $467K in common stock
Prelude Therapeutics stock surges on insider buying

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cognition Therapeutics stock logo

Cognition Therapeutics NASDAQ:CGTX

$0.67 +0.08 (+13.93%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.68 +0.01 (+1.44%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

KALA BIO stock logo

KALA BIO NASDAQ:KALA

$7.50 +0.73 (+10.78%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$7.60 +0.09 (+1.27%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Phio Pharmaceuticals stock logo

Phio Pharmaceuticals NASDAQ:PHIO

$2.33 -0.05 (-2.10%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.32 -0.01 (-0.60%)
As of 08/1/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Prelude Therapeutics stock logo

Prelude Therapeutics NASDAQ:PRLD

$0.83 +0.05 (+6.21%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.90 +0.07 (+8.66%)
As of 08/1/2025 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.